

**Amendments to the Claims**

Please amend Claims 1, 10 and 12-15. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently amended) ~~A medicament~~ An immunogenic composition comprising a recombinant poxvirus which is genetically engineered to be incapable of expressing a native A41L protein, together with a pharmaceutically acceptable carrier ~~for use in treatment or prophylaxis.~~
- 2-9. (Canceled)
10. (Currently amended) The ~~medicament~~ immunogenic composition according to claim 1, wherein the recombinant poxvirus is a genetically engineered vaccinia virus.
11. (Canceled)
12. (Currently amended) The ~~medicament~~ immunogenic composition according to claim 1, wherein the recombinant poxvirus is a genetically engineered Modified Vaccinia Ankara (MVA) virus.
13. (Currently amended) The ~~medicament~~ immunogenic composition according to claim 1, wherein the recombinant poxvirus is genetically engineered through deletion of a nucleotide sequences ~~sequence~~ encoding the native A41L protein.
14. (Currently amended) The ~~medicament~~ immunogenic composition according to claim 13, wherein the nucleotide ~~sequences are~~ sequence is set forth in SEQ ID NO: 1.
15. (Currently amended) The ~~medicament~~ immunogenic composition according to claim 1, which is incapable of expressing a chemokine-binding A41L protein.